Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samyr IM adjunctive therapy versus placebo in major depressive disorder with insufficient antidepressant response
2017-003074-14Phase 3Active
- Sponsor
- Mylan
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Samyr IM + antidepressant with Placebo IM + antidepressant (2 arms). Started Dec 2020; status: active.
02
Drugs
S-adenosylmethionine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-003074-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003074-14.